



# Dr. Vishnu Sreedath

MBBS, MD, DM (Medical Oncology)

Dr. Vishnu Sreedath is an ESMO Certified Medical Oncologist. He completed his MBBS from Government Medical College, Kozhikode, followed by MD in General Medicine from Stanley Medical College, and DM (Medical Oncology) from Madras Medical College. He is actively involved in oncology research and patient care and currently consults at Meitra Super Specialty Hospital, Kozhikode.

# **Medical Oncology**



#### Instructions

• The notes must be used in conjunction with the Marrow SS Medicine videos and should not be considered standalone material.

#### Please note:

- The information in this book has been printed based on the transcript of the Marrow SS Medicine videos.
- The information contained in this book is for educational purposes only. The content provided is not intended to substitute for professional medical advice, diagnosis or treatment.
- This book cannot be sold separately. It has been made available to only select eligible users who
  have an active subscription to Marrow SS Medicine videos.
- The text, images, slides, and other materials used in this book have been contributed by the faculty, who are subject matter experts. We have merely reproduced them as video transcripts in this book.
- The notes have been consciously designed in a way that is concise and revisable. To ensure this, we have intentionally added only the most relevant modules and images that are needed for you.
- Reasonable care has been taken to ensure the accuracy of the information provided in this book.
   Neither the faculty nor Marrow takes any responsibility for any liability or damages resulting from applying the information provided in this book.
- This set contains notes of all main videos published in the app until Jan 2025. You can find notes for any additional videos published after this date within the app under the videos section.

#### **All Rights Reserved**

No part of this publication shall be reproduced, copied, transmitted, adapted, modified or stored in any form or by any means, electronic, photocopying, recording or otherwise.

© Marrow

//ME801SS-SAP

# **Contents**

<b>Basics</b>	of	Onco	logy
---------------	----	------	------

1.	Basics of Paediatric Oncology	1
2.	Epidemiology and Molecular Biology of Paediatric Cancer	12
3.	Central Catheters in Oncology	27
Ne	euro-Oncology & Head and Neck Cancers	
4.	Head & Neck Cancer	31
5.	Metastatic HNSCC	41
6.	Oral Cavity Cancer	43
7.	Nasopharyngeal Cancer	48
8.	Brain Tumours : Part I	52
9.	Brain Tumors : Part II	69
10.	Neuroblastoma	87
11.	Retinoblastoma	99
Br	east & Thoracic Oncology	
12.	Small Cell Lung Cancer	115
13.	Mutation Driven Metastatic NSCLC	123
14.	Metastatic NSCLC without Driver Mutation	133
15.	Management of Non Metastatic NSCLC	140
16.	Pleural Mesothelioma	146
17.	Pulmonary Toxicity	151
18.	Superior Vena Cava Syndrome	159
19.	Thymoma and Thymic Carcinoma	165
20.	Breast Cancer - Basics	170
21.	DCIS	176
22.	Breast Cancer - Surgery & Radiation	179
23.	Metastatic Breast Cancer Management Part I	183

24.	Metastatic Breast Cancer Management Part II	189
25.	Systemic Treatment of Non Metastatic Breast Cancer : Part I	191
26.	Systemic Treatment of Non Metastatic Breast Cancer : Part II	194
27.	Breast Cancer - Miscellaneous : Part I	199
28.	Breast Cancer - Miscellaneous Part II	206
Ga	strointestinal Oncology	
29.	Oesophageal Cancer	211
30.	Liver Cancer	218
31.	Hepatic Tumors in Pediatrics	232
32.	Pancreatic Carcinoma	243
33.	Cholangiocarcinoma	250
34.	Lynch Syndrome	255
35.	Familial Adenomatous Polyposis	259
36.	Treatment of Carcinoma Colon	263
37.	Gastrointestinal Stromal Tumors	271
38.	Anal Canal Cancer	280
Ge	nito-Urinary Oncology	
39.	Renal Cell Carcinoma : Part I	287
40.	Renal Cell Carcinoma : Part II	299
41.	Wilms Tumor	306
42.	Urinary Bladder Cancer Part I	316
43.	Urinary Bladder Cancer Part II	324
44.	Testicular Germ Cell Tumors	331
45.	Testicular Germ Cell Tumors Part II	341
46.	Basics of Prostate Cancer	346
47.	Treatment of Prostate Cancer Part I	349
48	Treatment of Prostate Cancer - II	355

Gyneco	logic	Malig	nancies

49.	Endometrial Cancer	358
50.	Cervical Cancer	366
51.	Ovarian Cancer I	373
52.	Ovarian Cancer II	381
53.	PARP Inhibitors and Ovarian Cancer	383
54.	Granulosa Cell Tumors	387
55.	Ovarian Germ Cell Tumors	389
En	docrine Neoplasms	
56.	MEN I Syndrome	391
57.	MEN 2 Syndrome	399
58.	Medullary Thyroid Cancer	405
59.	Anaplastic Thyroid Carcinoma	412
60.	Differentiated Thyroid Cancer	416
Sk	in Neoplasms	
61.	Malignant Melanoma - Basics	427
62.	Malignant Melanoma - Treatment	433
Во	ne and Soft Tissue Neoplasms	
63.	Soft Tissue Tumors	439
64.	Soft Tissue Sarcoma (Paediatrics)	448
65.	Osteosarcoma	457
66.	Osteosarcoma (Paediatrics)	463
67.	Ewing Sarcoma	475
68.	Ewing Sarcoma (Paediatrics)	481
Ot	her Malignancies	
69.	Oncologic Emergencies	487
70.	Paediatric Germ Cell Tumour	507

# Other Topics in Oncology

71.	Tumour Lysis Syndrome	526
72.	Cardiotoxicity of Chemotherapy Agents	535
73.	Chemotherapy Induced Nausea and Vomiting	542
74.	Immunotherapy: I	549
75.	Immunotherapy : II	555
Ph	armacology	
76.	Pharmacology	562
77.	Alkylating Agents	568
78.	Taxanes	571
79.	Platinum Analogues	577
80.	Miscellaneous	583
81	Topoisomerase 1 Inhibitors and Vinca Alkaloids	507

# BASICS OF PAEDIATRIC ONCOLOGY

---- Active space -----


#### Introduction

00:00:23

#### Statistics:







@MARROW

80% of children with cancer will survive in high-income countries.

Only about 20% of children with cancer will survive in some low and middle income countries.

# Roadblocks to improved cancer survival:

- · Delayed diagnosis/misdiagnosis/no diagnosis.
- · Lack of awareness.
- Overlap of signs and symptoms of cancer with other infectious diseases.
- · Lack of diagnostic facilities.
- Symptoms of leukemia/lymphoma are often mistaken for more common nutritional deficiency/tuberculosis.
- many patients are empirically started on ATT.
- · Steroids are often used in peripheral centres without a diagnosis.

#### Retinoblastoma:

Early diagnosis: 100% survival.

Late diagnosis (Extraocular retinoblastoma): 20-30% survival.



Loss of red reflex: Early retinoblastoma.



extraocular retinoblastoma (Late).

Medical Oncology • v1.0 • Marrow SS Medicine

#### Cost of late diagnosis:

- Poor survival rates.
- · High treatment cost.

# Factors related to late diagnosis:

#### Patient related factors:

- · Infants: Dependent on caregivers for a diagnosis.
- · Adolescents: Ignoring the symptoms.

#### Health related factors:

- · Lack of diagnosis.
- · Lack of availability of cancer centres within reach.

#### Children at risk:

- I. Infections:
  - EBV infection: Hodgkin Lymphoma, Burkitt lymphoma, Post transplant lymphoproliferative disorder (PTLD), nasopharyngeal cancer.
  - · HIV: Kaposi sarcoma, 6 cell lymphoma.
  - Hep B and C: Hepatocellular carcinoma.
  - HPV: HPV associated cancer.
- a. Immunodeficiency syndromes.
- 3. Patients receiving immunosuppressive therapy: Higher risk of malignancy (PTLD and lymphomas).
- 4. Pediatric solid organ transplant recipients who are on prolonged thiopurine therapy: PTLD.
- 5. Childhood cancer survivors.
- 6. Exposure to allkylating agent, anthracycline, topoisomerase inhibitors.
- 7. Exposure to radiation.

# Signs and symptoms

00:10:31

#### Fever:

- Non specific symptom.
- One of the causes of prolonged fever of unknown origin (FuO): Occult malignancy.
- 10% or less of patients with FuO as the only symptom are later diagnosed with a malignancy.

3


# Lymphadenopathy:

m/c cause : Reactive hyperplasia (Benign). Enlarged lymph node could be due to :

- · Intrinsic cellular components.
- · Extrinsic cellular infiltration.

# Significant lymphadenopathy:

- · cervical >1 cm.
- · Axillary >1 cm.
- · Epitrochlear >0.5 cm.
- Inquinal >1.5 cm.




---- Active space -----

Generalized lymphadenopathy: Significant lymphadenopathy of a or more noncontiquous lymph nodes.

#### Note:

- · Palpable supraclavicular nodes should always be considered abnormal.
- Left-sided (Virchow) nodes suggest metastases from an intra-abdominal malignancy (Neuroblastoma).
- Right-sided nodes suggest intrathoracic disease.

# Lymphadenopathy Evaluation



# Indications of lymph node biopsy:

- Chronic, persistent, progressive adenopathy in the absence of any infectious etiology.
- · Any nodes > 2.5 cm in diameter in the absence of signs of infection.
- · Supraclavicular adenopathy.
- Systemic symptoms.

# Cautions for lymph node biopsy:

- Avoid upper cervical and inguinal areas: Commonly d/t infections.
- Lower cervical and axillary nodes are more reliable.
- Largest node should be biopsied.
- · Node should be removed intact with the capsule.
- Lymph node should be immediately submitted to the pathologist fresh or in sufficient tissue culture to prevent the tissue from drying out.
- The node must not be left in strong light (Subject to heat) and should not be wrapped in dry gauze (Drying): may produce a drying artefact.
- Fresh and frozen samples should be set aside for additional studies, as noted later.

#### Intracranial mass:

# Red flag signs of headache:

- Recurrent early morning vomiting.
- · Headache that awakens the child from sleep.
- · Incapacitating headache.
- Enlargement of head size (In infants).
- C/F associated with raised ICT (Intracranial tension).

Risk group	Clinical definition	Probability of brain tumor %	Diagnostic strategy
Low	Headache >6 months and no neurologic symptoms.	0.01	No imaging. Clinical follow-up and medical treatment.
Intermediate	migrane HA and no neurologic symptoms.	0.4	CT, MRI followed by biopsy or surgery.
High	Headache <6 months  and one clinical  predictor of space  occupying lesion.	4	mRI followed by biopsy or surgery.

#### Abdominal masses:

---- Active space -----

Palpable abdominal mass: m/c presenting feature.

Age of patient:

Neonatal period: Congenital malformation of GI and GU system.

· Childhood: malignant.

Site:

upper abdomen	mid abdomen	Lower abdomen
Neuroblastoma.  Wilms tumor.  Hepatoblastoma.  Lymphoma.	Lymphoma. Sarcoma. Germ cell tumor.	Germ cell tumor. Sarcoma. Lymphoma.

History and physical examination:

Systemic symptoms:

· Periorbital ecchymosis (Racoon eyes).

- · Subcutaneous nodules.
- · Bone pains.







Subcutaneous nodules, periorbital ecchymosis.

# Investigations:

- · Ultrasound abdomen.
- mass arising from liver: Serum alpha fetoprotein (AFP).
- Tumour markers:  $\beta$ -HCG.

# Bone pain:

Localized bone pain with limping:

- · Osteosarcoma.
- · Ewing sarcoma.

Features of malignant bone tumor:

- Cortical erosion.
- · Irregular mass.
- · Periosteal reaction.
- · White zone of transition.



malignant bone tumor.

Diffuse bone pain is a cardinal feature of acute leukemia. Differential diagnosis: Juvenile rheumatoid arthritis.

	Acute leukemia	JRA
Symptom manifestation	worse at night.	morning stiffness.
Involvement	Bones and joints.	Joints.
Constitutional symptoms	Present.	Present/absent.

Acute leukemia vs juvenile rheumatoid arthritis (JRA).


#### Mediastinal tumors

00:23:11

#### Parts of mediastinum:

Anterior mediastinum: Anteriorly by the sternum and posteriorly by pericardium.


middle mediastinum: Between the anterior border of pericardium and an imaginary line drawn  $\ensuremath{\text{I}}$  cm posterior to the anterior border of the vertebral bodies.



Parts of mediastinum.

Posterior mediastinum: Anteriorly by an imaginary line drawn I cm posterior to the anterior border of the vertebral bodies and posteriorly by the posterior paravertebral gutters.

#### Anterior mediastinal mass:



Anterior mediastinal mass.

Benign	malignant
	Non-Hodgkin's lymphoma
Teratoma	Hodgkin's disease
cystic hygroma	Teratoma with yolk sac tumour
Haemangioma	Seminoma
Thymic cyst	Desmoid
	Sarcoma
	Thymoma

Causes of anterior mediastinal mass.

#### middle mediastinal mass:





middle mediastinal mass.

Benign	malignant
Bronchogenic cyst	Hodgkin's disease
(Tracheal duplication cyst)	Non-Hodgkin's lymphoma
Teratoma	Teratoma
Plasma cell granuloma	Rhabdomyosarcoma
Cardiac rhabdomyoma	Other sarcomas

Causes of middle mediastinal mass.

#### Posterior mediastinal mass:



Pactoriar	mediatinal	mass
E OSTELLOL	II ICAIACII IAI	1110000

Benign	malignant
Ganglioneuroma Neurofibroma Enterogenous cyst Teratoma (Rare) Lipoma Leiomyoma	Neuroblastoma, Ganglioneuroblastoma Neurofibrosarcoma Sarcoma Liposarcoma Leiomyosarcoma Sarcoma

Causes of posterior mediastinal mass.

# Lung tumors

00:26:03

- Primary malignancies of the lung and tracheobronchial tree: Rare.
- Inflammatory myofibroblastic tumor: m/c lung tumor in pediatrics.
- Bronchial carinoid: Intense contrast enhancement related to their fibrovascular stromal component.
- mucoepidermoid carcinoma.
- · Bronchogenic carcinoma.

# Pleuropulmonary blastomas (PPB):

# Type 1:

- · Purely cystic tumors occurring <2 years of age.
- median age of 10 months, 5-year DFS: 90%.

# Type II:

- · Cystic and solid tumors.
- median age of 35 months.

#### Type III:

- Solid tumors, median age of 41 months.
- Surgical resection is recommended if feasible,
   followed by chemotherapy and/or radiation therapy,
   intracavitary chemotherapy.
- 5-year DFS: 50-60%.
- Associated with germline pathogenic DICERI variants.
- Susceptible to other tumors:

Cystic nephromas.

Ovarian stromal sex cord tumors.

Thyroid and other endocrine tumors.

Embryonal rhabdomyosarcoma.

Brain tumors.







Pleuropulmonary blastomas.

#### Chest wall tumors

00:27:22

may arise from bone or soft tissues.

m/c: metastatic rib lesions (Neuroblastoma,

Langerhans cell histiocytosis, lymphoma, leukemia).

m/c paediatric chest wall primary malignancies:

- · Rhabdomyosarcoma.
- · Extraosseous Ewing sarcoma.
- · PNET of the chest (Askin tumor).



Chest wall tumor.

# Primary bone malignancies:

- · Ewing sarcoma.
- · Osteosarcoma.

may arise from the ribs, thoracic vertebrae, or scapulae and manifest as chest wall masses.

Non malignant chest wall masses:

- Neurofibromas.
- Hemangiomas, vascular malformations.

- · Aneurysmal bone cysts.
- · Osteochondromas.
- · Healing rib fractures.
- · Osteomyelitis.
- · Developmental variations of the thoracic cage.

# Indications of immediate evaluation of back pain:

- Bowel/bladder dysfunction.
- · Paresis.
- · Gait abnormalities.
- · Paraesthesia.

Risk of spinal cord compression: Emergency. Immediate MRI scanning. Start dexamethasone.

# Peripheral blood abnormalities

00:29:33

# Investigations:

- I. Complete blood counts:
- · Pancytopenia/bicytopenia
- · Leukocytosis.
- a. Peripheral smear (PS): Presence of blasts.




Indications for bone marrow studies:

- · Patients with pancytopenia/more than one depressed cell line.
- · Presence of blasts on peripheral smear.
- Presence of leucoerythroblastic changes on PS.
- Association with unexplained lymphadenopathy, bone pain, or hepatosplenomegaly.
- Association with an anterior mediastinal mass.

# Diagnosis of leukemia:

- ≥a0% bone marrow lymphoblasts in bone marrow study.
- Peripheral blood sample may be substituted if a sufficient level of circulating lymphoblasts is present.



Blast cells on PS.

Stains to distinguish lymphoblasts from myeloblasts:

- Wright-Giemsa-stained bone marrow aspirates.
- Hematoxylin and eosin (HgE) stained biopsies.

# Features of lymphoblast:

- High nucleus—to-cytoplasm ratio.
- · Absence of nucleoli.
- · Smaller size.

# 4. Flow cytometry.

# 5. Immunophenotyping:

8 cells: CD10, CD19, CD20, CD45, Kappa, lambda.

T cells: CD2, CD3, CD4, CD5, CD7, CD8, CD45.

myelomonocytic cells: CDIIb, CDI3, CDI4, CDI5, CDI6, CD33, CD34, CD45, CDI17, HLA-DR.

# 6. Chromosomal analysis and banding:

Essential for the identification of aneuploidy, microscopic chromosomal anomalies, and some translocations.

#### Common translocation in ALL:

- t(ia; ai): m/c translocation in childhood ALL, favorable prognosis.
- t(1; 19): Bad prognosis.
- t(9;22): very poor outcome.
- Ilq23 rearrangements: Poor outcome.
- t(5;14).


used for risk stratification.

#### Note:

In case of suspicion of leukemia, do not give steroids during a blood transfusion or in case of transfusion reaction as it can delay the diagnosis.

#### modalities of treatment:

---- Active space -----



# THE GOAL OF THE GLOBAL INITIATIVE IS TO ACHIEVE AT LEAST A



AND TO REDUCE SUFFERING FOR ALL CHILDREN WITH CANCER BY 2030.

### 1 MILLION

CHILDREN WITH CANCER CAN BE SAVED IN THE NEXT DECADE.



# Key home message:

- · Childhood cancer is a highly curable disease.
- Increase awareness about symptoms and signs of childhood cancer.
- Early diagnosis.
- · Early referral to the pediatric oncology unit.

# EPIDEMIOLOGY AND MOLECULAR BIOLOGY OF PAEDIATRIC CANCER

#### Introduction

00:00:17

Tissue homeostasis depends on the regulated cell division and self-elimination (Programmed cell death) of each of its constituent members except its stem cells.

A tumor arises as a result of:

- · uncontrolled cell division.
- · Failure for self-elimination.

Alterations in genes responsible for the deregulated control mechanisms that are the hallmarks of cancer cells:


- · Proto-oncogenes.
- · Tumor supressor genes.
- DNA stability genes/DNA repair genes.

#### Genes involved

00:01:18

#### Oncogenes:

It is a proto-oncogene  $\rightarrow$  mutated  $\rightarrow$  Leads to signals that cause uncontrolled growth i.e., cancer.



mechanism of oncogenes